“Now the first stage of clinical trials is underway for a drug that was created at the site of the Natsimbio immunobiological company of the Rostec state corporation - a specific anticoid immunoglobulin,” Olga Eikhler, head of the department of medical support for conversion and extreme work and the blood service of the FMBA, in the fields of Vostochny, said in an interview with TASS. economic forum.
In July, the Federal Biomedical Agency developed and registered a new test system for detecting the most relevant strains of the coronavirus.
It is noted that the unique set of reagents "AmpliTest SARS-CoV-2 VOC v.2" was developed by scientists of the Center for Strategic Planning and Management of Medical and Biological Health Risks of the FMBA to identify the RNA of the SARS-CoV-2 coronavirus of the genetic lines "alpha", "beta" , "Gamma" and "delta" based on the determination of their characteristic mutations in the S-protein of the virus by the method of polymerase chain reaction.
The kit was registered on July 21, it was introduced into production and is ready for serial production.
Earlier, FMBA began clinical trials of its coronavirus vaccine.